244
Views
15
CrossRef citations to date
0
Altmetric
Letter

Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure

, , , , &
Pages 2527-2529 | Received 19 Apr 2012, Accepted 30 Apr 2012, Published online: 12 Jun 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Lu Zhang, Miao-yan Zhang, Xin-xin Cao, Dao-bin Zhou, David C. Fajgenbaum, Yu-jun Dong & Jian Li. (2022) A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD. Leukemia & Lymphoma 63:3, pages 618-626.
Read now

Articles from other publishers (14)

Tomoki Suichi, Sonoko Misawa, Yukari Sekiguchi, Kazumoto Shibuya, Keigo Nakamura, Hiroki Kano, Yuya Aotsuka, Ryo Otani, Marie Morooka, Shokichi Tsukamoto, Yusuke Takeda, Naoya Mimura, Chikako Ohwada, Emiko Sakaida & Satoshi Kuwabara. (2022) Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. Internal Medicine 61:17, pages 2567-2572.
Crossref
Ji Ma, Xiaoyue Wang, Hui Lu, Zhihao Liang & Liang Wang. (2022) Ixazomib Combined With Autologous Stem Cell Transplantation for POEMS Syndrome: A Case Report and Meta-Analysis. Technology in Cancer Research & Treatment 21, pages 153303382211236.
Crossref
Xue-min Gao, Yan-ying Yu, Hao Zhao, Hao Cai, Lu Zhang, Xin-xin Cao, Dao-bin Zhou & Jian Li. (2021) Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome. Annals of Hematology 100:11, pages 2755-2761.
Crossref
Yan-ying Yu, Xue-min Gao, Hao Zhao, Hao Cai, Jun Feng, Lu Zhang, Xin-xin Cao, Daobin Zhou & Jian Li. (2021) Treatment and outcomes of POEMS syndrome: changes in the past 20 years. Blood Cancer Journal 11:8.
Crossref
Tomoki Suichi & Sonoko Misawa. (2020) Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome: Diagnosis, treatment and the current status in Japan. Clinical and Experimental Neuroimmunology 11:2, pages 101-108.
Crossref
Chiara Briani, Marta Campagnolo, Marco Luigetti, Federica Lessi & Fausto Adami. 2020. Dysimmune Neuropathies. Dysimmune Neuropathies 129 143 .
Jin Deng, Wei Kong, Xiaoyang Mou, Shuaiqun Wang & Weiming Zeng. (2018) Identifying novel candidate biomarkers of RCC based on WGCNA analysis. Personalized Medicine 15:5, pages 381-394.
Crossref
Swaroopa Pulivarthi & Murali Krishna Gurram. (2018) An atypical presentation of POEMS syndrome with IgG kappa type M protein and normal VEGF level. Journal of Cancer Research and Therapeutics 14:3, pages 679-681.
Crossref
Dimitrios C. Ziogas, Angela Dispenzieri & Evangelos Terpos. 2018. Multiple Myeloma and Other Plasma Cell Neoplasms. Multiple Myeloma and Other Plasma Cell Neoplasms 177 189 .
Lina Wu, Yue Li, Fang Yao, Chongmei Lu, Jian Li, Weixun Zhou & Jiaming Qian. (2017) Portal hypertension as the initial manifestation of POEMS syndrome: a case report. BMC Hematology 17:1.
Crossref
Rahma Warsame, Uday Yanamandra & Prashant Kapoor. (2017) POEMS Syndrome: an Enigma. Current Hematologic Malignancy Reports 12:2, pages 85-95.
Crossref
Wei Ye, Chen Wang, Qian-Qian Cai, Hao Cai, Ming-Hui Duan, Hang Li, Xin-Xin Cao, Dao-Bin Zhou & Jian Li. (2015) Renal impairment in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome: incidence, treatment and outcome. Nephrology Dialysis Transplantation, pages gfv261.
Crossref
Yoshimi Ishii, Etsuko Yamazaki, Yasufumi Ishiyama, Eri Yamamoto, Yukako Hattori, Maki Hagihara, Naoto Tomita & Yoshiaki Ishigatsubo. (2013) Successful treatment of POEMS syndrome with bortezomib and dexamethasone, combined with radiotherapy, and followed by autologous stem cell transplantation. International Journal of Hematology 98:6, pages 723-728.
Crossref
Jian Li & Dao-bin Zhou. (2013) New advances in the diagnosis and treatment of POEMS syndrome. British Journal of Haematology 161:3, pages 303-315.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.